GHRP-2 Peptide Shows Promise for Diagnosing Rare Pituitary Tumors

Thyrotropin-producing pituitary adenomas (TSHomas) are rare tumors that secrete excess thyroid-stimulating hormone (TSH), leading to hyperthyroidism. Diagnosing TSHomas can be challenging due to their rarity and the need to differentiate them from other causes of hyperthyroidism or pituitary dysfunction. Current diagnostic methods often lack sufficient specificity or sensitivity, highlighting the critical need for more accurate and reliable diagnostic tools.

The study revealed a distinct difference in TSH response between TSHoma patients and healthy controls following GHRP-2 administration. Healthy individuals exhibited a robust increase in TSH levels, whereas TSHoma patients showed a significantly blunted response. GHRP-2 administration led to a significantly blunted TSH response in TSHoma patients, with a mean TSH increase of only 18% from baseline compared to a robust 115% increase in healthy controls (p<0.001). Furthermore, the diagnostic sensitivity of GHRP-2 for TSHomas was determined to be 90%, with a specificity of 85% when using a TSH response threshold of a 50% increase from baseline. While GHRP-2 effectively stimulated GH secretion in both groups (a 3.8-fold increase in TSHoma patients and a 4.2-fold increase in controls), the differential TSH response proved to be the key diagnostic indicator.